Annovis Bio, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ANVS New York 2836 www.annovisbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Annovis Bio, Inc.

Annovis to Attend the AAIC 2025 with Four Poster Presentations - Jun 26th, 2025 6:00 am
We Think Annovis Bio (NYSE:ANVS) Needs To Drive Business Growth Carefully - Jun 22nd, 2025 8:30 am
Annovis Announces NYSE Acceptance of Plan to Regain Listing Compliance - Jun 19th, 2025 4:30 am
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy - Jun 11th, 2025 10:00 am
Annovis to Host Webinar and Live Q&A on June 24, 2025 - Jun 5th, 2025 6:00 am
Annovis Provides Corporate Updates and Reports First Quarter 2025 Financial Results - May 13th, 2025 2:30 pm
Annovis Bio Appoints Hui Liu as Director of Biostatistics - Apr 29th, 2025 6:00 am
Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE - Mar 27th, 2025 2:30 pm
Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program - Mar 25th, 2025 6:00 am
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Mar 21st, 2025 3:05 pm
Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment - Mar 11th, 2025 6:00 am
Annovis to Host Patients’ Live Forum on February 27, 2025 - Feb 19th, 2025 6:30 am
Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference - Feb 7th, 2025 6:00 am
Annovis begins treatment of subjects in Alzheimer’s trial - Feb 6th, 2025 9:21 am
Annovis Bio announces first patients entered Phase 3 study of buntanetap - Feb 6th, 2025 6:20 am
Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease - Feb 5th, 2025 6:00 am
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering - Feb 4th, 2025 2:31 pm
Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering - Feb 3rd, 2025 4:22 am
Annovis Bio, Inc. Announces Proposed Public Offering - Jan 31st, 2025 6:14 pm
Annovis Bio granted U.S. patent covering buntanetap - Jan 15th, 2025 6:11 am